Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 9/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | PRKACG | P22612 | 1/20 | 0.52 |
| ▸ | PRKACB | P22694 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 2/20 | 0.52 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.52 |
| ▸ | EEF2K | O00418 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172346 | 0.89 | HTT (0.55) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL12562405 | 0.85 | CHRM4 (0.56) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL3177294 | 0.85 | MAPT (0.62) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL19769227 | 0.83 | KDM4E (0.65) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL13392971 | 0.83 | HTT (0.47) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL3176192 | 0.82 | ALDH1A1 (0.51) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL3174607 | 0.81 | MAPT (0.49) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL431864 | 0.79 | HTT (1.00) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL6111557 | 0.74 | IKBKB (0.59) | HTTNPC1RAB9AKMT2ANCOA3 | |
| SCHEMBL15222916 | 0.74 | CHRM4 (0.63) | HTTNPC1MAPTKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | claimed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | claimed |
| WO-2005076861-A2 | COMPOUNDS THAT INHIBIT HIV PARTICLE FORMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | NAKAMURA, ROBERT | 2018-01-18 | — | — | US | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | disclosed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | disclosed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | disclosed |
| WO-2005076861-A2 | COMPOUNDS THAT INHIBIT HIV PARTICLE FORMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | HTT 2608/4885NPC1 2091/4885RAB9A 1654/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | HTT 2588/4885NPC1 1976/4885RAB9A 1518/4885 |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | REV1, VPS51, FLOT1 | HTT 3892/4885NPC1 68/4885RAB9A 378/4885 |
| US-20180015077-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTION | CD4, CCR5, MMP8 | HTT 3323/4885NPC1 27/4885RAB9A 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.